Healthcare Services

Fabry Disease Treatment Industry Expansion Forecast Showing Market Size of $3.34 Billion by 2030 at 7.8% CAGR

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Fabry Disease Treatment Market During 2026–2030?

The fabry disease treatment market has experienced significant expansion in recent years. It is projected to grow from $2.27 billion in 2025 to $2.48 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.8%. This historical growth can be attributed to several factors, including improved awareness of rare genetic disorders, the approval of enzyme replacement therapies, the expansion of genetic testing, an increase in specialty hospitals, and enhanced patient advocacy.

The fabry disease treatment market size is anticipated to undergo significant expansion in the next few years, with expectations for it to reach $3.34 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. The projected growth in this period can be attributed to various factors, including advancements in gene therapy, the increasing utilization of personalized medicine, improvements in newborn screening programs, the wider availability of oral therapies, and a rise in rare disease funding. Prominent trends anticipated during the forecast timeframe encompass the increasing adoption of enzyme replacement therapy, a heightened focus on early genetic diagnosis, the expansion of oral chaperone therapies, burgeoning research into gene therapy approaches, and enhanced patient access to treatments for rare diseases.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16421&type=smp

Which Economic Or Industry Drivers Are Impacting The Fabry Disease Treatment Market?

The growing occurrence of renal diseases is projected to propel the expansion of the fabry disease treatment market in the coming years. Renal diseases, also known as kidney diseases, are any conditions that impair the kidneys’ ability to function. The number of renal disease cases is increasing due to genetic predispositions, lifestyle choices, environmental factors, and existing health conditions. Fabry disease results from the accumulation of globotriaosylceramide (Gb3) in kidney cells, leading to damage and dysfunction, which emphasizes the critical necessity for early detection and intervention to prevent kidney complications. For instance, in March 2023, according to the International Society of Nephrology (ISN), a Belgium-based professional society, approximately 850 million people worldwide were living with chronic kidney disease (CKD), representing an increase compared to prior years. Therefore, the rising prevalence of renal diseases is driving the growth of the fabry disease treatment market.

How Are The Various Segments Of The Fabry Disease Treatment Market Categorized?

The fabry disease treatment market covered in this report is segmented –

1) By Treatment: Substrate Reduction Therapy, Enzyme Replacement Therapy, Chaperone Treatment, Other Treatments

2) By Route Of Administration: Oral Route, Intravenous Route

3) By Disease Severity: Classic Fabry Disease, Late-Onset Fabry Disease

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold), Other Substrate Reduction Therapies

2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme), Agalsidase Alfa (Replagal), Other Enzyme Replacement Therapies

3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold), Other Chaperone Therapies

4) By Other Treatments: Gene Therapy, Symptomatic Treatment

What Trends Are Affecting The Expansion Of The Fabry Disease Treatment Market?

Leading companies within the Fabry disease treatment market are focusing on the development of plant cell-based treatments to bolster therapeutic effectiveness, reduce healthcare expenditures, and elevate patient outcomes through innovative and sustainable methodologies. This approach to Fabry disease treatment involves utilizing plant cells to synthesize the enzymes deficient in affected individuals. These plant-derived enzymes serve as a therapeutic option to replace the missing or malfunctioning enzymes within the body, aiming to alleviate symptoms and improve the health status of patients with Fabry disease. A notable example is the approval of ELFABRIO in May 2023 for Chiesi Global Rare Diseases, an Italy-based pharmaceutical company, and Protalix BioTherapeutics Inc., an Israel-based pharmaceutical company. ELFABRIO offers an alternative treatment choice for individuals with Fabry disease. It functions as an enzyme replacement therapy (ERT) where the recombinant human a-Galactosidase-A enzyme is cultivated in plant-cell culture and subsequently modified with PEGylation to significantly extend its half-life. This treatment is designed to decrease administration frequency, enhance patient convenience, and improve the comprehensive management of Fabry disease symptoms, ultimately improving patients’ quality of life.

Which Major Firms Influence Developments In The Fabry Disease Treatment Market?

Major companies operating in the fabry disease treatment market are Sanofi S.A., Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc., Sangamo Therapeutics Inc., Protalix BioTherapeutics, Avrobio Inc., Freeline Therapeutics Holdings PLC, M6P Therapeutics Inc., Yuhan Corporation, Orchard Therapeutics Ltd., Regenxbio Inc., Synlogic Inc., AceLink Therapeutics Inc., Greenovation Biotech GmbH, CANbridge Life Sciences Ltd., Sigilon Therapeutics Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., Daiichi Sankyo Company Ltd., Audentes Therapeutics Inc., Genesis Therapeutics Inc., Idorsia Pharmaceuticals Ltd., JCR Pharmaceuticals Co Ltd., ISU Abxis Co Ltd.

Read the full fabry disease treatment market report here:

https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

What Are The Top-Performing Regions Within The Fabry Disease Treatment Market?

North America was the largest region in the fabry disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Fabry Disease Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16421&type=smp

Browse Through More Reports Similar to the Global Fabry Disease Treatment Market 2026, By The Business Research Company

Plantar Fasciitis Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/plantar-fasciitis-treatment-global-market-report

Gardner Syndrome Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/gardner-syndrome-treatment-global-market-report

Lysosomal Disease Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795